Literature DB >> 9488395

Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice.

R R Yuan1, G Spira, J Oh, M Paizi, A Casadevall, M D Scharff.   

Abstract

The isotype and epitope specificities of antibodies both contribute to the efficacy of antibodies that mediate immunity to Cryptococcus neoformans, but the relationship between these properties is only partially understood. In this study, we analyzed the efficacy of protection of two sets of immunoglobulin G (IgG) isotype switch variants from two IgG3 monoclonal antibodies (MAbs) which are either not protective or disease enhancing, depending on the mouse model used. The two IgG3 MAbs 3E5 and 4H3 have different epitope specificities. Protection experiments were done with A/JCr mice infected intravenously with C. neoformans and administered with 3E5 IgG3 and its IgG1, IgG2a, and IgG2b switch variants. These experiments revealed that IgG1, IgG2b, and IgG2a were each more effective than IgG3. For 4H3 IgG3 and its IgG1 and IgG2b switch variants, the relative efficacy was IgG2b > IgG1 >> IgG3. The combination of 3E5 IgG3 and 4H3 IgG3 was more deleterious than either IgG3 alone. All IgG isotypes were opsonic for mouse bronchoalveolar cells, with the relative efficacy being IgG2b > IgG2a > IgG1 > IgG3. These results (i) confirm that a nonprotective IgG3 MAb can be converted to a protective MAb by isotype switching, (ii) indicate that the efficacy of protection of an IgG1 MAb can be increased by isotype switching to another subclass, (iii) show that protective and nonprotective IgG MAbs are opsonic, and (iv) provide additional evidence for the concept that the efficacy of the antibody response to C. neoformans is dependent on the type of MAb elicited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488395      PMCID: PMC108015          DOI: 10.1128/IAI.66.3.1057-1062.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

Review 1.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

2.  Simultaneous expression of kappa and lambda light chains in a murine IgG3 anti-Cryptococcus neoformans hybridoma cell line.

Authors:  G Spira; R Yuan; M Paizi; M Weisendal; A Casadevall
Journal:  Hybridoma       Date:  1994-12

Review 3.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  Immune complexes increase nitric oxide production by interferon-gamma- stimulated murine macrophage-like J774.16 cells.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  J Leukoc Biol       Date:  1995-04       Impact factor: 4.962

5.  Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.

Authors:  S Mukherjee; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

6.  Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody.

Authors:  R Yuan; A Casadevall; G Spira; M D Scharff
Journal:  J Immunol       Date:  1995-02-15       Impact factor: 5.422

7.  Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils.

Authors:  Z M Dong; J W Murphy
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

8.  Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion.

Authors:  Z M Dong; J W Murphy
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

9.  Antibody response that protects against disseminated candidiasis.

Authors:  Y Han; J E Cutler
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes.

Authors:  A Vecchiarelli; C Retini; D Pietrella; C Monari; C Tascini; T Beccari; T R Kozel
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  32 in total

1.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  Peptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniae.

Authors:  S L Harris; M K Park; M H Nahm; B Diamond
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.

Authors:  Wendy A Szymczak; Rani S Sellers; Liise-anne Pirofski
Journal:  Am J Pathol       Date:  2012-02-16       Impact factor: 4.307

Review 4.  The protective role of immunoglobulins in fungal infections and inflammation.

Authors:  Sri Ramulu Elluru; Srini V Kaveri; Jagadeesh Bayry
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

5.  The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.

Authors:  Oscar Zaragoza; Mauricio Alvarez; Andrew Telzak; Johanna Rivera; Arturo Casadevall
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

6.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 7.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

Review 8.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  6-O-Branched Oligo-β-glucan-Based Antifungal Glycoconjugate Vaccines.

Authors:  Guochao Liao; Zhifang Zhou; Jun Liao; Luning Zu; Qiuye Wu; Zhongwu Guo
Journal:  ACS Infect Dis       Date:  2015-12-30       Impact factor: 5.084

10.  Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.

Authors:  Loïc Guillot; Scott F Carroll; Robert Homer; Salman T Qureshi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.